Cancers & treatments·Regimen libraryFirst line

DRd (daratumumab + lenalidomide + dexamethasone)

Checked 2026-09-09

Newly diagnosed transplant-ineligible myeloma (MAIA); relapsed myeloma (POLLUX)

One cycle

every 28 days

28-day cycle, until progressionSubcutaneousOral Daily oral course

Components

Drug	Dose	Route	Days
Daratumumab Monoclonal antibody (anti-CD38)	16 mg/kg IV or 1,800 mg SC: weekly cycles 1-2, every 2 weeks cycles 3-6, then every 4 weeks	SC	D1, 8, 15, 22
Lenalidomide Immunomodulatory drug (cereblon E3 ligase modulator)	25 mg once daily	Oral	D1-21
Dexamethasone	40 mg weekly (20 mg over 75 years)	Oral	D1, 8, 15, 22

Cycles

until progression

28-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Used in

Multiple myeloma

Products

DaratumumabLenalidomide

Source

MAIA, NEJM 2019

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.